À¶Ý®ÊÓƵ

Pump-priming the translational pipeline: ICiC awards

161101_toxicology_charingcross_006_208248_001-tiny

The aims to develop Imperial’s early translational research portfolio by providing pilot funding to bridge the gaps between ‘discovery research’ and attraction of follow-on funding for clinical translation of novel therapeutics, devices and diagnostics. These awards form a crucial part of the À¶Ý®ÊÓƵ Imperial BRC’s translational pipeline, by initiating ‘pull-through’ of new science from our Faculties of Medicine, Natural Sciences and Engineering.

This year, a total ICiC fund of £1.8m was available from our MRC Confidence-in-Concept award, together with contributions from the À¶Ý®ÊÓƵ Imperial BRC, the Imperial College Wellcome Institutional Strategic Support Fund (ISSF), EPSRC Impact Acceleration Accounts and HEIF funding, and the À¶Ý®ÊÓƵ Royal Marsden/ICR BRC. In addition, our partnership with AstraZeneca offers the AZ Innovation Fund, which is run as part of the ICiC. Following the sixth ICiC competition (in 2018), the cross-College panel, chaired by Professor Roberto Solari, selected 26 projects for funding, each worth up to £80,000.

The À¶Ý®ÊÓƵ Imperial BRC directly funded the following projects:

Prof Julian Marchesi, Prof Mark Thursz, Dr Julie McDonald & Dr Benjamin Mullish: Bile salt hydrolase and valerate: novel treatments to prevent and treat Clostridium difficile infection

Prof Molly Stevens & Prof Charles Coombes: State-of-the-art Raman single particle analysis of extracellular vesicles as biomarkers for cancer diagnosis and treatment

Dr Lorenzo Picinali: Refining and evaluating the Binaural Intervention Package (BIP) for bilateral cochlear implant users

Prof Ramesh Wigneshweraraj: Host environment dependent delivery of antibacterials by engineered phage

As part of the AZ Innovation Fund, the following projects were selected:

Dr David Mann & Prof Alan Armstrong: Targeted covalent drug discovery for Rac1

Prof Geoff Baldwin: Cellular delivery of PROTACS as a novel therapeutic approach

Dr Paul McKay, Dr Anna Blakney & Prof Robin Shattock: Optimization of Modular, Exteriorly-Loaded Lipid Nanoparticles for mRNA Delivery in Human Skin Explants

For the full list of successful proposals, and further information on the scheme, please .